Turnstone Biologics Corporation

https://www.turnstonebio.com

LinkedIn: https://www.linkedin.com/company/turnstone-biologics

Turnstone Biologics, a clinical-stage biotechnology company, is developing new medicines to treat solid tumors by pioneering a differentiated approach with tumor-infiltrating lymphocyte (TIL) therapy, a clinically validated technology. Turnstone’s innovative TIL therapy, which is designed to extend the efficacy of TILs to multiple solid tumor indications by selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) for tumor eradication, represents the foundational therapeutic modality driving the Company’s cancer immunotherapy pipeline. The Company’s lead Selected TIL therapy candidate, TIDAL-01, is currently being evaluated in two Phase 1b studies in patients with multiple solid tumor indications. Turnstone is also advancing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with the Company’s novel viral immunotherapy. *

	Start	2023-03-16 existent
	Industry	TIL technology (Tumor Infiltrating Lymphocyte)

	Street	9310 Athena Circle Suite 300
	City	92037 La Jolla, CA
	Tel	+1-347-897-5988
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Scailyte AG. (3/16/23). "Press Release: Scailyte Announces Collaboration with Turnstone Biologics". Basel.

		Record changed: 2023-07-23

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Turnstone Biologics Corporation

[1] Scailyte AG. (3/16/23). "Press Release: Scailyte Announces Collaboration with Turnstone Biologics". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]